Cervical cancer treatment market is expected to grow at a Considerable CAGR by 2026
The global cervical cancer treatment market is expected to expand at a CAGR of 5.2% from 2018 to 2026.
(IINews) - The latest market report published by Credence Research, Inc. “Global Cervical Cancer Treatment Market - Growth, Future Prospects, Competitive Analysis, 2018 - 2026,” the global cervical cancer treatment market is expected to expand at a CAGR of 5.2% from 2018 to 2026.
Market Insights
According to the latest research citings of World Health Organization (WHO) in 2018, approximately 570,000 new cases if cervical cancer were reported which eventually represents 6.6% of all female cancers. The early manifestation of cervical cancer are vaginal bleeding after sexual intercourse with excruciating pain. The 2 main types of cervical cancer are squamous cell carcinoma and adenocarcinoma. Early diagnosis and vaccination with Gardasil can prevent the advent of cervical cancer. In the last decade there has been a paradigm shift in the treatment regimen from chemotherapy to targeted therapy. Biologics in the phase III clinical trials such as nimotuzumab and atezolizumab will provide a positive thrust to the cervical cancer treatment market growth.
Get Sample with more graphs and details for better understanding: https://www.credenceresearch.com/sample-request/59521
Browse the full report Cervical Cancer Treatment Market - Growth, Future Prospects, Competitive Analysis, 2018 – 2026 report at https://www.credenceresearch.com/report/cervical-cancer-treatment-market
Chemotherapy is reigning the product segment for cervical cancer treatment market. Placitaxel, cisplatin, carboplatin, gemcitabine are given either alone or in combination with radiation therapy for patients suffering with advanced stage cervical cancer. The combination therapy is helpful but causes severe adverse effects. Cervical hysterectomy is helpful in women suffering with early stage cervical cancer. Targeted drug therapy will be the fastest growing market on account of its excellent clinical outcomes, dose tolerability and patient compliance.
North America presently maintains supremacy in the regional segment for cervical cancer treatment market. According to Center for Disease Control And Prevention (CDC), cervical cancer is the second most common type of cancer in women after breast cancer resulting in mortality due to lack of early screening and medical intervention. Rising public health awareness and affordable reimbursement scenario drive the cervical cancer treatment market growth in North America. In Europe cervical cancer is responsible for the mortality of 70% patient actively diagnosed with cervical cancer. Presence of key players such as F.Hoffman La-Roche AG., Merck & Co., Inc., and GlaxoSmithkline, Plc. etc. propel the cervical cancer treatment market growth in the European Region. Asia Pacific will be the fastest growing market during the forecast period owing to the presence of huge generic market and proactive government policies to fight cervical cancer.
Biopharmaceutical companies having a strong foothold in the cervical cancer treatment market are, Allergan, Plc., Biocon Ltd., CooperSurgical, Inc., Eli Lilly & Company, F.Hoffman La-Roche AG, GlaxoSmithkline Plc., Ethicon, Inc., Merck & Co., Inc., Teva Pharmaceutical Industries Ltd. and Varian Medical Systems, Inc.
Key Market Movements:
•Increasing cases of women being diagnosed for cervical cancer throughout the globe
•Rising public health awareness and affordable reimbursement scenario for the generic drugs employed for the treatment of cervical cancer
•Vaccination such as Gardasil is helpful in prevention of HPV infection and strong biologics pipeline with drugs in phase III clinical trials such as nimotuzumab and atezolizumab
Browse the full report Cervical Cancer Treatment Market - Growth, Future Prospects, Competitive Analysis, 2018 – 2026 report at https://www.credenceresearch.com/report/cervical-cancer-treatment-market
About Us
Credence Research is a worldwide market research and counseling firm that serves driving organizations, governments, non legislative associations, and not-for-benefits. We offer our customers some assistance with making enduring enhancements to their execution and understand their most imperative objectives. Over almost a century, we''ve manufactured a firm extraordinarily prepared to this task.
Who we are
Credence Research is a worldwide firm, containing more than 15 research consultants and almost 100 research and information professionals. Our customers mirror our worldwide nature. Around 45% are in Europe, 30% in the Americas, 13% in Asia Pacific and 12% in the Middle East and Africa. Our firm is intended to work as one. We are a solitary global research organization united by a solid arrangement of qualities, concentrated on customer effect.
Blog: http://www.newsnasdaq.com
Credence Research Inc
105 N 1st ST #429
SAN JOSE
CA 95103
United States
Toll Free(US/CANADA): +1-800-361-8290
Email: sales(at)credenceresearch.com
Themen in diesem Fachartikel:
Unternehmensinformation / Kurzprofil:
Credence Research Inc
105 N 1st ST #429
SAN JOSE
CA 95103
United States
Toll Free(US/CANADA): +1-800-361-8290
Email: sales(at)credenceresearch.com
Datum: 18.01.2019 - 09:03 Uhr
Sprache: Deutsch
News-ID 1688265
Anzahl Zeichen: 0
Kontakt-Informationen:
Ansprechpartner: Robson Tolson
Stadt:
SANJOSE
Telefon: 18003618290
Kategorie:
Vermischtes
Anmerkungen:
Dieser Fachartikel wurde bisher 69 mal aufgerufen.
Der Fachartikel mit dem Titel:
"Cervical cancer treatment market is expected to grow at a Considerable CAGR by 2026
"
steht unter der journalistisch-redaktionellen Verantwortung von
Credence Research (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).